SCHEMBL10587746

SCHEMBL10587746

ClCc1cn2ccc(Cl)cc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.45
KDM4E B2RXH2 6/20 0.42
ALDH1A1 P00352 4/20 0.42
POLB P06746 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 7/20 0.41
NPC1 O15118 7/20 0.41
RAB9A P51151 7/20 0.41
MAPT P10636 5/20 0.41
KLKB1 P03952 1/20 0.39
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
PKM P14618 1/20 0.36
HTR1A P08908 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17229376 0.84 AKR1B1 (0.44) AKR1B1KDM4EALDH1A1POLBTDP1
SCHEMBL15767323 0.84 AKR1B1 (0.44) AKR1B1KDM4EALDH1A1POLBTDP1
SCHEMBL17221376 0.84 AKR1B1 (0.44) AKR1B1KDM4EALDH1A1POLBTDP1
Hydrochloric Acid SCHEMBL22613762 0.83 AKR1B1 (0.44) AKR1B1KDM4EALDH1A1POLBTDP1
SCHEMBL974491 0.81 METTL3 (0.44) KDM4EALDH1A1POLBTDP1L3MBTL1
SCHEMBL8172945 0.81 KDM4E (0.63) KDM4EALDH1A1POLBTDP1L3MBTL1
SCHEMBL15767586 0.80 AKR1B1 (0.42) AKR1B1KDM4EALDH1A1POLBTDP1
SCHEMBL5074964 0.79 AKR1B1 (0.49) AKR1B1KDM4EALDH1A1POLBTDP1
SCHEMBL754044 0.77 AKR1B1 (0.38) AKR1B1KDM4EALDH1A1POLBTDP1
SCHEMBL1905278 0.77 KDM4E (0.38) KDM4EALDH1A1POLBTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2740730-B1 DIBENZOOXEPIN DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2016-11-16 EP disclosed
US-8969345-B2 Dibenzooxepin derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-03-03 US disclosed
US-20140163008-A1 DIBENZOOXEPIN DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-06-12 US disclosed
EP-2740730-A1 DIBENZOOXEPIN DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2014-06-11 EP disclosed
US-20130131021-A1 ANALOGUES OF CILOSTAZOL CONCERT PHARMACEUTICALS INC. (US) 2013-05-23 US disclosed
EP-0322153-A2 Heterocyclic oxophtalazinyl acetic acids PFIZER INC. (US) 1989-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131021-A1 ANALOGUES OF CILOSTAZOL PDE3A, PDE3B, PDE5A AKR1B1 813/4885KDM4E 1163/4885ALDH1A1 1189/4885
US-20140163008-A1 DIBENZOOXEPIN DERIVATIVE PPARA, PPARG, PPARD AKR1B1 616/4885KDM4E 1605/4885ALDH1A1 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.